Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Zealand Pharma

< Previous 1 2 3 Next >
News headline image
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Announces Financial Results for the First Quarter of 2024
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Announces Financial Results for the Full Year 2023
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma completes registration of capital increase
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
From Zealand Pharma
Via GlobeNewswire
News headline image
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma Announces Financial Results for the First Nine Months of 2023
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek
From Zealand Pharma
Via GlobeNewswire
News headline image
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
From Zealand Pharma
Via GlobeNewswire
News headline image
SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma to participate in upcoming healthcare conferences in September 2023
From Zealand Pharma
Via GlobeNewswire
News headline image
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
From Zealand Pharma
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.